What is the official website of Regeneron Medical ?

The official website of Regeneron Medical is https://regeneronmedical.com.

What is Regeneron Medical's cybersecurity risk score?

Regeneron Medical has an AI-generated cybersecurity risk score of null out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Regeneron Medical experienced?

According to Rankiteo, Regeneron Medical currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Regeneron Medical been affected by any supply chain cyber incidents ?

According to Rankiteo, Regeneron Medical has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Regeneron Medical have SOC 2 Type 1 certification ?

According to Rankiteo, Regeneron Medical is not certified under SOC 2 Type 1.

Does Regeneron Medical have SOC 2 Type 2 certification ?

According to Rankiteo, Regeneron Medical does not hold a SOC 2 Type 2 certification.

Does Regeneron Medical comply with GDPR ?

According to Rankiteo, Regeneron Medical is not listed as GDPR compliant.

Does Regeneron Medical have PCI DSS certification ?

According to Rankiteo, Regeneron Medical does not currently maintain PCI DSS compliance.

Does Regeneron Medical comply with HIPAA ?

According to Rankiteo, Regeneron Medical is not compliant with HIPAA regulations.

Does Regeneron Medical have ISO 27001 certification ?

According to Rankiteo,Regeneron Medical is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Regeneron Medical operate in ?

Regeneron Medical operates primarily in the Biotechnology Research industry.

How many employees does Regeneron Medical have ?

Regeneron Medical employs approximately 0 people worldwide.

Does Regeneron Medical own any subsidiaries ?

Regeneron Medical presently has no subsidiaries across any sectors.

How many LinkedIn followers does Regeneron Medical have ?

Regeneron Medical's official LinkedIn profile has approximately 616 followers.

What is the NAICS classification code for Regeneron Medical ?

Regeneron Medical is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Regeneron Medical have a Crunchbase profile ?

No, Regeneron Medical does not have a profile on Crunchbase.

Does Regeneron Medical have a LinkedIn profile ?

Yes, Regeneron Medical maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/regeneron-medical.

How many cybersecurity incidents has Regeneron Medical experienced ?

As of August 5, 2026, Rankiteo reports that Regeneron Medical has not experienced any cybersecurity incidents.

How many peer or competitor companies does Regeneron Medical have ?

Regeneron Medical has an estimated 4,736 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Regeneron Medical

Boost Score +25 with badge (5 left)

/1000

Fair

/1000

Critical

Regeneron Medical Vendor Cyber Rating & Cyber Score

regeneronmedical.com

Add Your Compliance Badge

Regeneron Medical Affairs aims to provide the latest medical and scientific information and educational resources for US healthcare professionals. By following Regeneron Medical on LinkedIn, you confirm your status as a US healthcare professional and agree to receive scientific information intended solely for healthcare professionals. Please visit www.regeneron.com/social-media-terms for guidelines to help the online community understand how social media channels may be used by Regeneron. If you have any questions about a Regeneron product, please contact us at 1-844-REGN-MID (1-844-734-6643).

Regeneron Medical A.I CyberSecurity Scoring

Scoring History

Regeneron Medical

Regeneron Medical CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Regeneron Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Regeneron Medical

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Regeneron Medical in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Regeneron Medical in 2026.

Incident Types Regeneron Medical vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Regeneron Medical in 2026.

Incident History - Regeneron Medical (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Regeneron Medical Subsidiaries

Regeneron Medical

Biotechnology Research

Website: https://regeneronmedical.com

Company Size: 0

RegeneronBiotechnology

OxularBiotechnology

Loading…

Regeneron Medical Similar Companies

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Amgen

amgen.com

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Loading…

NEWS

Regeneron Medical CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

August 11, 2025 07:00 AM

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Cencora, The Lash Group, and their affiliates have agreed to pay $40 million to settle class action data breach litigation over a February...

Read Article

August 07, 2025 07:00 AM

Regeneron Leadership Set for Morgan Stanley, Wells Fargo Healthcare Conference Presentations

Management to share insights at prestigious healthcare conferences including Morgan Stanley and Cantor events. View complete schedule and...

Read Article

July 07, 2025 07:00 AM

Bankruptcy Court Approves Sale of 23andMe

A federal bankruptcy court has approved the sale of direct-to-consumer genetic testing company 23andMe to TTAM Research Institute.

Read Article

July 02, 2025 07:00 AM

US FDA approves Regeneron's blood cancer therapy

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called...

Read Article

June 02, 2025 07:00 AM

Regeneron's weight-loss drug helps patients on Wegovy preserve muscle

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination...

Read Article

May 21, 2025 07:00 AM

Gujarat teen behind 50+ cyberattacks on govt websites during 'Operation Sindoor' arrested by Gujarat ATS

Gujarat ATS arrested Jasim Shahnawaz Ansari, an 18-year-old, for alleged cyber terrorism, including DDoS attacks on over 50 Indian...

Read Article

May 19, 2025 07:00 AM

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction,...

Read Article

April 22, 2025 07:00 AM

Regeneron to invest over $3 billion to boost US manufacturing

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth,...

Read Article

January 15, 2025 08:00 AM

17 health systems invest in Truveta Genome Project

The health systems, Illumina, and Regeneron have invested $320M in what Truveta calls the largest and most diverse database for patient care.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-45537

SUMMARY

OpenSIPS is a Session Initiation Protocol (SIP) server implementation. In versions prior to 3.6.6 and 4.0.0-rc1, the construct_uri() function concatenates multiple URI components (protocol, username, domain, port, params) into a fixed 1024-byte global BSS buffer without any bounds checking. When a routing script calls construct_uri() with an attacker-controlled username, a combined component length exceeding 1024 bytes overflows the buffer, corrupting adjacent global data with attacker-controlled content. The overflow reaches disable_503_translation, a global flag controlling SIP 503 response handling, allowing an attacker to deterministically set the flag via the URI username and alter the server's routing behavior for subsequent messages. Because the same buffer is shared with contact_builder(), the overflow also corrupts that function's data, and without a memory sanitizer the adjacent globals are silently overwritten on every request containing a long username. This issue has been fixed in versions 3.6.6 and 4.0.0-rc1.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-18819

SUMMARY

A security vulnerability has been detected in RackTables up to 0.22.0/e5fff9f8aab339798ed47e8c6d7d977ed97a82bd. This vulnerability affects unknown code. The manipulation leads to cross-site request forgery. The attack is possible to be carried out remotely. The exploit has been disclosed publicly and may be used. The project maintainer confirms: "[I]t seems plausible, in that RackTables does not at this time have any CSRF prevention. You may assign a CVE ID to this, but there is no guarantee it will be handled in urgent, or even timely, manner, or at all."

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-18818

SUMMARY

A weakness has been identified in Ehco1996 django-sspanel up to 2023.12.26. This affects the function TicketDetailView of the file apps/sspanel/views.py of the component Support Ticket Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. The vendor was contacted early about this disclosure but did not respond in any way. This vulnerability only affects products that are no longer supported by the maintainer.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-70620

SUMMARY

Odysseus before commit 87babb5 contains a server-side request forgery vulnerability that allows admin-privileged attackers to direct the server to probe internal network resources by supplying arbitrary URLs to the embedding endpoint configuration without scheme, host, IP range, or DNS rebind validation. Attackers can submit loopback addresses, RFC 1918 ranges, or link-local addresses through the embedding endpoint API to partially read responses from cloud instance metadata services, internal APIs, and other hosts reachable from the server.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-70619

SUMMARY

Odysseus before commit bf325f6 contains a missing authorization vulnerability that allows authenticated non-admin users to manage server-wide embedding backend configuration by invoking endpoint management routes that verify session authentication but omit the admin authorization guard. Attackers can supply an attacker-controlled URL to overwrite the embedding backend persisted in the endpoint configuration file and process environment, causing all subsequent embedding operations including chat messages, RAG queries, memory entries, and vault text to be transmitted in plaintext to the attacker-controlled destination, or delete the endpoint configuration to deny embedding service to all users.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…